Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions

摘要: The epidemics of overweight and obesity has resulted in a significant increase non alcoholic fatty liver disease (NAFLD), potentially progressive condition. Currently, related hepatopathy represents therefore the main cause pediatric chronic disease. first choice treatment at all ages is weight loss and/or lifestyle changes, however compliance very poor pharmacological approach become necessary. In present article we systematic literature review focusing on established NALFD drugs (ursodeoxycholic acid, insulin sensitizers, antioxidants) innovative therapeutic options as well. Regarding former ones, pilot study highlighted that ursodeoxycholic acid not efficient transaminases levels bright liver. Similarly, recent large scale, multicenter randomized clinical trial (TONIC study) showed also sensitizers antioxidant vitamin E have scarce effects serum transaminase levels. Among series novel approaches acting recently proposed different pathomechanisms, probiotics seem hitherto most interesting reasonable option for their safety tolerability. Toll-like receptors modifiers, Pentoxifylline, Farnesoid X agonists been still poorly investigated, will need further studies before becoming possible promising strategies.